Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$102.80 USD
-2.21 (-2.10%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $102.78 -0.02 (-0.02%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Ligand Pharmaceuticals Incorporated falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 131 | 196 | 277 | 186 | 120 |
Cost Of Goods | 11 | 53 | 62 | 30 | 11 |
Gross Profit | 121 | 143 | 215 | 156 | 109 |
Selling & Adminstrative & Depr. & Amort Expenses | 109 | 140 | 136 | 130 | -698 |
Income After Depreciation & Amortization | 12 | 3 | 79 | 26 | 807 |
Non-Operating Income | 52 | 35 | -12 | -9 | 25 |
Interest Expense | 1 | 2 | 20 | 27 | 36 |
Pretax Income | 64 | 36 | 47 | -11 | 797 |
Income Taxes | 10 | 41 | -10 | -8 | 167 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 54 | -5 | 57 | -3 | 629 |
Extras & Discontinued Operations | -2 | -28 | 0 | 0 | 0 |
Net Income (GAAP) | 52 | -33 | 57 | -3 | 629 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 47 | 55 | 147 | 78 | 871 |
Depreciation & Amortization (Cash Flow) | 35 | 52 | 68 | 53 | 63 |
Income After Depreciation & Amortization | 12 | 3 | 79 | 26 | 807 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 17.76 | 16.87 | 17.25 | 16.19 | 19.76 |
Diluted EPS Before Non-Recurring Items | 2.91 | 1.94 | 4.65 | 3.13 | 2.11 |
Diluted Net EPS (GAAP) | 2.94 | -1.98 | 3.31 | -0.18 | 31.85 |
Fiscal Year end for Ligand Pharmaceuticals Incorporated falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 41.53 | 30.98 | 28.10 | 32.87 | 26.37 |
Cost Of Goods | 2.91 | 2.88 | 1.64 | 3.49 | 1.67 |
Gross Profit | 38.63 | 28.10 | 26.46 | 29.38 | 24.70 |
SG&A, R&D, and Dept/Amort Expenses | 57.72 | 25.11 | 29.82 | 26.31 | 26.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | -19.09 | 2.99 | -3.36 | 3.07 | -1.98 |
Non-Operating Income | -45.02 | 110.60 | 20.59 | -15.22 | 5.44 |
Interest Expense | 1.27 | 0.14 | 0.13 | 0.00 | 0.28 |
Pretax Income | -65.39 | 113.45 | 17.10 | -12.14 | 3.17 |
Income Taxes | -13.48 | 27.31 | -1.09 | -1.87 | 0.88 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -51.91 | 86.14 | 18.19 | -10.27 | 2.29 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -51.91 | 86.14 | 18.19 | -10.27 | 2.29 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 18.03 | 18.12 | 17.68 | 17.38 | 17.73 |
Diluted EPS Before Non-Recurring Items | 0.92 | 0.80 | 0.79 | 0.71 | 1.10 |
Diluted Net EPS (GAAP) | -2.88 | 4.75 | 1.07 | -0.59 | 0.13 |